百克生物(688276.SH):目前公司mRNA技術平台主要圍繞RSV疫苗等疫苗進行佈局
格隆匯2月8日丨百克生物(688276.SH)近日在接待機構投資者調研時表示,公司與傳信生物簽訂投資協議,藉助傳信生物在mRNA疫苗研究技術方面具有的核心優勢,助力公司加快建設mRNA平台技術並拓展應用;完善mRNA疫苗相關知識產權體系;開發適用於不同目的的mRNA遞送技術。目前,公司mRNA技術平台主要圍繞RSV疫苗、癌症治療性疫苗及HSV-2等疫苗進行佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.